Evaluating amikacin dosage regimens in intensive care unit patients: A pharmacokinetic/pharmacodynamic analysis using Monte Carlo simulation

International Journal of Antimicrobial Agents

Volumn 42, Issue 2, 2013, Pages 155-160

  Zazo, Hinojal ^a,b   Martín Suárez, Ana ^a,b   Lanao, José M ^a,b  

^a UNIVERSITY OF SALAMANCA   (Spain)

^b INSTITUTO DE INVESTIGACIÓN BIOMÉDICA DE SALAMANCA IBSAL   (Spain)

Author keywords

Amikacin; Dosage regimens; ICU; Monte Carlo simulation; PK PD model

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; TOBRAMYCIN;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; AREA UNDER THE CURVE; ARTICLE; BACTERIAL GROWTH; COLONY FORMING UNIT; CONTROLLED STUDY; CORRELATION COEFFICIENT; DISTRIBUTION VOLUME; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG EFFICACY; HUMAN; INTENSIVE CARE UNIT; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; PRIORITY JOURNAL; PROBABILITY; SEPSIS; STEADY STATE;

AMIKACIN; DOSAGE REGIMENS; ICU; MONTE CARLO SIMULATION; PK/PD MODEL;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; AMIKACIN; ANTI-BACTERIAL AGENTS; CRITICAL ILLNESS; HUMANS; INTENSIVE CARE UNITS; MICROBIAL SENSITIVITY TESTS; MODELS, STATISTICAL; PLASMA; TIME FACTORS;

EID: 84880267744     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2013.04.021     Document Type: Article

References (29)

1. N. Petrosillo, C.M. Drapeau, M. Agrafiotis, and M.E. Falagas Some current issues in the pharmacokinetics/pharmacodynamics of antimicrobials in intensive care Minerva Anestesiol 76 2010 509 524
2. H. Hanberger, D. Arman, H. Gill, V. Jindrak, S. Kalenic, and A. Kurcz Surveillance of microbial resistance in European intensive care units: a first report from the Care-ICU programme for improved infection control Intensive Care Med 35 2009 91 100
3. E.A. Radigan, N.A. Gilchrist, and M.A. Miller Management of aminoglycosides in the intensive care unit J Intensive Care Med 25 2010 327 342
4. J. Mensa, J.M. Gatell, J.E. García-Sanchéz, E. Letang, and E. López-Suñé Guía de terapeútica antimicrobiana 2009 Antares Barcelona, Spain
5. R.S. Rea, and B. Capitano Optimizing use of aminoglycosides in the critically ill Semin Respir Crit Care Med 28 2007 596 603
6. R.S. Rea, B. Capitano, R. Bies, K.L. Bigos, R. Smith, and H. Lee Suboptimal aminoglycoside dosing in critically ill patients Ther Drug Monit 30 2008 674 681
7. V.A. Bhattaram, C. Bonapace, D.M. Chilukuri, J.Z. Duan, C. Garnett, and J.V. Gobburu Impact of pharmacometric reviews on new drug approval and labeling decisions - a survey of 31 new drug applications submitted between 2005 and 2006 Clin Pharmacol Ther 81 2007 213 221 (Pubitemid 46174818)
8. E.I. Nielsen, O. Cars, and L.E. Friberg Pharmacokinetic/pharmacodynamic (PK/PD) indices of antibiotics predicted by a semimechanistic PKPD model: a step toward model-based dose optimization Antimicrob Agents Chemother 55 2011 4619 4630
9. C. Adembri, and A. Novelli Pharmacokinetic and pharmacodynamic parameters of antimicrobials: potential for providing dosing regimens that are less vulnerable to resistance Clin Pharmacokinet 48 2009 517 528
10. J.A. Roberts, C.M. Kirkpatrick, and J. Lipman Monte Carlo simulations: maximizing antibiotic pharmacokinetic data to optimize clinical practice for critically ill patients J Antimicrob Chemother 66 2011 227 231
11. S. Romano, M. Del Mar Fdez de Gatta, V. Calvo, E. Mendez, A. Domínguez-Gil, and J.M. Lanao Influence of clinical diagnosis in the population pharmacokinetics of amikacin in intensive care unit patients Clin Drug Investig 15 1998 435 444 (Pubitemid 28243012)
12. M.M. Mar Fernández de Gatta, M. Victoria Calvo, R. Ardanuy, A. Domínguez-Gil, J.M. Lanao, and S.R. Moreno Evaluation of population pharmacokinetic models for amikacin dosage individualization in critically ill patients J Pharm Pharmacol 61 2009 759 766
13. N. Revilla, A. Martín-Suárez, M.P. Pérez, F.M. González, and M. Fernández de Gatta Mdel Vancomycin dosing assessment in intensive care unit patients based on a population pharmacokinetic/pharmacodynamic simulation Br J Clin Pharmacol 70 2010 201 212
14. F. Alvarez-Lerma, P. Olaechea, S. Grau, M. Marín, A. Domínguez, and J. Mártinez-Lanao Recommendations for antibiotic monitoring in ICU patients Enferm Infecc Microbiol Clin 26 2008 230 239 [in Spanish] (Pubitemid 351534798)
15. Abbott Laboratories Abbottbase Pharmacokinetics System (PKS) 1991 Abbott Laboratories Abbott Park, IL
16. V.H. Tam, K.R. Ledesma, G. Vo, S. Kabbara, T.P. Lim, and M. Nikolaou Pharmacodynamic modeling of aminoglycosides against Pseudomonas aeruginosa and Acinetobacter baumannii: identifying dosing regimens to suppress resistance development Antimicrob Agents Chemother 52 2008 3987 3993
17. J. Fishbain, and A.Y. Peleg Treatment of Acinetobacter infections Clin Infect Dis 51 2010 79 84
18. V.H. Tam, A.N. Schilling, and M. Nikolaou Modelling time-kill studies to discern the pharmacodynamics of meropenem J Antimicrob Chemother 55 2005 699 706 (Pubitemid 40691849)
19. J. Palomino, and J. Pachón Aminoglycosides Enferm Infecc Microbiol Clin 21 2003 105 114 [in Spanish]
20. J.A. Roberts, and J. Lipman Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and pharmacodynamics of sepsis Clin Pharmacokinet 45 2006 755 773
21. J.A. Roberts, and J. Lipman Pharmacokinetic issues for antibiotics in the critically ill patient Crit Care Med 37 2009 840 851
22. C.R. Frei, N.P. Wiederhold, and D.S. Burgess Antimicrobial breakpoints for Gram-negative aerobic bacteria based on pharmacokinetic-pharmacodynamic models with Monte Carlo simulation J Antimicrob Chemother 61 2008 621 628 (Pubitemid 351321137)
23. R.L. Iman, J.C. Helton, and J.E. Campbell An approach to sensitivity analysis of computer models: part I - introduction, input variable selection and preliminary variable assessment J Quality Technology 13 1981 174 183
24. GoldSim Technology Group LLC GoldSim user's guide. v.10.1 2010 GoldSim Technology Group LLC Issaquah, WA
25. H. Mikamo, K. Tanaka, and K. Watanabe Evaluation of efficacy of oral quinolone against Streptococcus pneumoniae and Haemophilus influenzae with the use of Monte Carlo simulation Jpn J Antibiot 59 2006 468 473 [in Japanese] (Pubitemid 46212604)
26. V.H. Tam, P.S. McKinnon, R.L. Akins, G.L. Drusano, and M.J. Rybak Pharmacokinetics and pharmacodynamics of cefepime in patients with various degrees of renal function Antimicrob Agents Chemother 47 2003 1853 1861 (Pubitemid 36637805)
27. A.A. el-Tahtawy, A.J. Jackson, and T.M. Ludden Comparison of single and multiple dose pharmacokinetics using clinical bioequivalence data and Monte Carlo simulations Pharm Res 11 1994 1330 1336 (Pubitemid 24287415)
28. J.L. Kuti, C. Ong, M. Lo, D. Melnick, N. Soto, and D.P. Nicolau Comparison of probability of target attainment calculated by Monte Carlo simulation with meropenem clinical and microbiological response for the treatment of complicated skin and skin structure infections Int J Antimicrob Agents 28 2006 62 68 (Pubitemid 43949338)
29. P.L. Toutain, J.R. del Castillo, and A. Bousquet-Melou The pharmacokinetic-pharmacodynamic approach to a rational dosage regimen for antibiotics Res Vet Sci 73 2002 105 114 (Pubitemid 35175230)